Login

Financial Snapshot

Revenue
TTM
$5.208B
Gross Margin
TTM
60.59%
Net Income
TTM
-$219.0M
Current Assets
2026 Q1
Current Liabilities
2026 Q1
Current Ratio
2026 Q1
152.53%
Total Assets
2026 Q1
Total Liabilities
2026 Q1
Book Value
2026 Q1
$6.452B
Cash
2026 Q1
P/E
Last 4 Quarters
N/A
Free Cash Flow
TTM
$1.000M

Stock Price

Loading...
Market Cap: $5.3409 Billion

About Bausch + Lomb Corp

Bausch + Lomb Corp. develops, manufactures, and markets eye health products. The company is headquartered in Vaughan, Ontario and currently employs 13,000 full-time employees. The company went IPO on 2022-05-06. The company operates through three segments: Vision Care, Pharmaceuticals, and Surgical. Vision Care segment includes both a contact lens and a consumer eye care business that consists of contact lens care products, over-the-counter eye drops and eye vitamins. Pharmaceuticals segment consists of generic pharmaceutical products for post-operative treatments and treatments for a number of eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes and retinal diseases. Surgical segment consists of medical device equipment, consumables, instruments and technologies for the treatment of cataracts, corneal and vitreous and retinal eye conditions, which includes delivery systems, phacoemulsification equipment and other surgical instruments and devices for cataract surgery. Its brands consist of PreserVision, Biotrue, Artelac, Alaway, Mioclear, Ocuvite, ScoutPro, XIIDRA, Vyzulta, Lotemax, Prolensa, Minims, INFUSE, and many more.

Industry: Ophthalmic Goods

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support